November 24, 2015
2 min read

ISAR DESIRE 4: Paclitaxel-coated balloon is safe in treating in DES restenosis

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

The use of a scoring balloon plus a paclitaxel-coated balloon yielded angiographically superior results vs. a paclitaxel-coated balloon alone in patients with restenosis with limus-eluting stents, according to findings from the ISAR DESIRE 4 trial presented at the annual TCT scientific symposium.

“In the ISAR DESIRE 4 trial, we showed in patients presenting with DES restenosis in limus-eluting stents, that paclitaxel-coated balloon-based strategies confirmed a high clinical safety profile out to one year,” Robert A. Byrne, PhD, of Deutsches Herzzentrum, Munich, Germany, said in a presentation.

“Moreover, neointimal modification with scoring balloon significantly improves the angiogenic, anti-restenotic efficacy of paclitaxel-coated balloon angioplasty,” he said.

In the prospective, randomized, active-controlled, multicenter trial, Byrne and colleagues evaluated 252 patients with drug-eluting stent implantation restenosis enrolled between June 2012 and December 2014 from four sites in Germany.  

The researchers randomized patients to either treatment with scoring balloon plus paclitaxel-coated balloon (n = 125) or paclitaxel-coated balloon alone (n = 127). A total of 203 patients (80.4%) were seen for angiographic follow-up at 6 to 8 months. Clinical follow-up took place at 12 months.

There were no significant differences between groups in baseline clinical or demographic characteristics. The study’s primary endpoint was percent diameter stenosis on angiographic follow-up. Secondary endpoints included binary restenosis, target lesion revascularization, death/MI and target lesion thrombosis.  

The percent diameter stenosis was 40.4% ± 21.4% in the scoring balloon (SCB) plus paclitaxel-coated balloon (PCB) group compared with 35% ± 16.8 for the PCB alone group (P = .047). With SCB plus PCB, patients also had lower rates of binary restenosis than with PCB alone (18.5% vs. 32%, P = .03).

Similar rates were seen between the SCB plus PCB and PCB alone groups in target lesion revascularization (16.8% vs. 22.6%, respectively, P = .25) and death/MI (3.3% vs. 3.4%, respectively, P > .99).

“In terms of further safety endpoints, such as target lesion thrombosis, there were no events in either group — zero percent with both scoring balloons and control therapy,” Byrne said. – by Jennifer Byrne


Byrne RA. Neointimal Modification in Scoring Balloon and Efficacy of Drug-Coated Balloon Therapy in Patients with Restenosis in Drug-Eluting Coronary Stents. Presented At: TCT Scientific Symposium; Oct. 11-15, 2015; San Francisco.

Disclosure: Byrne reports receiving lecture fees from B. Braun Melsungen AG, Biotronik and Boston Scientific.